Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment

IntroductionTreatment of type 2 diabetes (T2D) remains a significant challenge because of its multifactorial nature and complex metabolic pathways. There is growing interest in finding new therapeutic targets that could lead to safer and more effective treatment options. Takeda G protein-coupled rec...

Full description

Saved in:
Bibliographic Details
Main Authors: Ojochenemi A. Enejoh, Chinelo H. Okonkwo, Hector Nortey, Olalekan A. Kemiki, Ainembabazi Moses, Florence N. Mbaoji, Abdulrazak S. Yusuf, Olaitan I. Awe
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Chemistry
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fchem.2024.1503593/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841553872996270080
author Ojochenemi A. Enejoh
Chinelo H. Okonkwo
Hector Nortey
Olalekan A. Kemiki
Ainembabazi Moses
Ainembabazi Moses
Florence N. Mbaoji
Abdulrazak S. Yusuf
Olaitan I. Awe
author_facet Ojochenemi A. Enejoh
Chinelo H. Okonkwo
Hector Nortey
Olalekan A. Kemiki
Ainembabazi Moses
Ainembabazi Moses
Florence N. Mbaoji
Abdulrazak S. Yusuf
Olaitan I. Awe
author_sort Ojochenemi A. Enejoh
collection DOAJ
description IntroductionTreatment of type 2 diabetes (T2D) remains a significant challenge because of its multifactorial nature and complex metabolic pathways. There is growing interest in finding new therapeutic targets that could lead to safer and more effective treatment options. Takeda G protein-coupled receptor 5 (TGR5) is a promising antidiabetic target that plays a key role in metabolic regulation, especially in glucose homeostasis and energy expenditure. TGR5 agonists are attractive candidates for T2D therapy because of their ability to improve glycemic control. This study used machine learning-based models (ML), molecular docking (MD), and molecular dynamics simulations (MDS) to explore novel small molecules as potential TGR5 agonists.MethodsBioactivity data for known TGR5 agonists were obtained from the ChEMBL database. The dataset was cleaned and molecular descriptors based on Lipinski’s rule of five were selected as input features for the ML model, which was built using the Random Forest algorithm. The optimized ML model was used to screen the COCONUT database and predict potential TGR5 agonists based on their molecular features. 6,656 compounds predicted from the COCONUT database were docked within the active site of TGR5 to calculate their binding energies. The four top-scoring compounds with the lowest binding energies were selected and their activities were compared to those of the co-crystallized ligand. A 100 ns MDS was used to assess the binding stability of the compounds to TGR5.ResultsMolecular docking results showed that the lead compounds had a stronger affinity for TGR5 than the cocrystallized ligand. MDS revealed that the lead compounds were stable within the TGR5 binding pocket.DiscussionThe combination of ML, MD, and MDS provides a powerful approach for predicting new TGR5 agonists that can be optimised for T2D treatment.
format Article
id doaj-art-266733a85c5e44b0b6155bddb8fa0afc
institution Kabale University
issn 2296-2646
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Chemistry
spelling doaj-art-266733a85c5e44b0b6155bddb8fa0afc2025-01-09T06:11:01ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462025-01-011210.3389/fchem.2024.15035931503593Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatmentOjochenemi A. Enejoh0Chinelo H. Okonkwo1Hector Nortey2Olalekan A. Kemiki3Ainembabazi Moses4Ainembabazi Moses5Florence N. Mbaoji6Abdulrazak S. Yusuf7Olaitan I. Awe8Genetics, Genomics and Bioinformatics Department, National Biotechnology Research and Development Agency, Abuja, NigeriaDepartment of Pharmacy, National Hospital Abuja, Abuja, NigeriaDepartment of Clinical Pathology, Noguchi Memorial Institute for Medical Research, College of Health Science, University of Ghana, Accra, GhanaMolecular and Tissue Culture Laboratory, Babcock University, Ilisan-remo, Ogun State, NigeriaAfrican Centers of Excellence in Bioinformatics and data intensive sciences, Department of Immunology and Microbiology, Makerere University, Makerere, UgandaInfectious Disease Institute (IDI), Makerere University, Kampala, UgandaDepartment of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu, NigeriaDepartment of Biochemistry, Faculty of Basic Health Science, Bayero University, Kano, NigeriaAfrican Society for Bioinformatics and Computational Biology, Cape Town, South AfricaIntroductionTreatment of type 2 diabetes (T2D) remains a significant challenge because of its multifactorial nature and complex metabolic pathways. There is growing interest in finding new therapeutic targets that could lead to safer and more effective treatment options. Takeda G protein-coupled receptor 5 (TGR5) is a promising antidiabetic target that plays a key role in metabolic regulation, especially in glucose homeostasis and energy expenditure. TGR5 agonists are attractive candidates for T2D therapy because of their ability to improve glycemic control. This study used machine learning-based models (ML), molecular docking (MD), and molecular dynamics simulations (MDS) to explore novel small molecules as potential TGR5 agonists.MethodsBioactivity data for known TGR5 agonists were obtained from the ChEMBL database. The dataset was cleaned and molecular descriptors based on Lipinski’s rule of five were selected as input features for the ML model, which was built using the Random Forest algorithm. The optimized ML model was used to screen the COCONUT database and predict potential TGR5 agonists based on their molecular features. 6,656 compounds predicted from the COCONUT database were docked within the active site of TGR5 to calculate their binding energies. The four top-scoring compounds with the lowest binding energies were selected and their activities were compared to those of the co-crystallized ligand. A 100 ns MDS was used to assess the binding stability of the compounds to TGR5.ResultsMolecular docking results showed that the lead compounds had a stronger affinity for TGR5 than the cocrystallized ligand. MDS revealed that the lead compounds were stable within the TGR5 binding pocket.DiscussionThe combination of ML, MD, and MDS provides a powerful approach for predicting new TGR5 agonists that can be optimised for T2D treatment.https://www.frontiersin.org/articles/10.3389/fchem.2024.1503593/fullTGR5type 2 diabetesmachine learningmolecular dockingmolecular dynamics simulationCOCONUT database
spellingShingle Ojochenemi A. Enejoh
Chinelo H. Okonkwo
Hector Nortey
Olalekan A. Kemiki
Ainembabazi Moses
Ainembabazi Moses
Florence N. Mbaoji
Abdulrazak S. Yusuf
Olaitan I. Awe
Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment
Frontiers in Chemistry
TGR5
type 2 diabetes
machine learning
molecular docking
molecular dynamics simulation
COCONUT database
title Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment
title_full Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment
title_fullStr Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment
title_full_unstemmed Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment
title_short Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment
title_sort machine learning and molecular dynamics simulations predict potential tgr5 agonists for type 2 diabetes treatment
topic TGR5
type 2 diabetes
machine learning
molecular docking
molecular dynamics simulation
COCONUT database
url https://www.frontiersin.org/articles/10.3389/fchem.2024.1503593/full
work_keys_str_mv AT ojochenemiaenejoh machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment
AT chinelohokonkwo machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment
AT hectornortey machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment
AT olalekanakemiki machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment
AT ainembabazimoses machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment
AT ainembabazimoses machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment
AT florencenmbaoji machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment
AT abdulrazaksyusuf machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment
AT olaitaniawe machinelearningandmoleculardynamicssimulationspredictpotentialtgr5agonistsfortype2diabetestreatment